Engflag

Jest

Quick links to important sections

Jest

Jest_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jest

Property Description
Active ingredient Chlorpheniramine Maleate
Form Oral forms (tablet, capsule, liquid/syrup)
Pharmacological class H₁ Receptor Antagonist (Antihistamine)
Common use Symptomatic relief of allergic conditions
Origin Synthetic First-Generation Compound

Jest: Definition and Pharmacological Classification

Jest is a medicinal product whose active component is Chlorpheniramine Maleate, a synthetic chemical compound used to relieve symptoms associated with allergic reactions. This medication is classified as a first-generation antihistamine belonging to the alkylamine derivative class. Its classification as a single active ingredient product means Chlorpheniramine Maleate is the sole therapeutic substance responsible for the drug's primary effect. The official literature confirms its function as an H₁ receptor antagonist, meaning it directly counteracts the effects of histamine in the body.

The classification as a first-generation compound signifies it was among the initial groups of medications developed to combat the effects of histamine. This status is chemically important because it results in a broader range of physiological effects compared to newer analogues, a property clinically recognized.

What is Chlorpheniramine Maleate and How Does it Help?

The core therapeutic component, Chlorpheniramine Maleate, functions as a competitive H₁ receptor antagonist, which is the fundamental action that helps relieve allergy symptoms. The drug works by preventing the body's natural chemical, histamine, from binding to and activating the H₁ receptors on target cells.

This mechanism of H₁ antagonism is generally helpful for reducing the permeability of capillaries and muscle contractions that cause allergic swelling and congestion. Scientific consensus supports that H₁ antagonists are effective in providing general symptomatic relief from hypersensitivity reactions. The overall purpose of this action is to offer temporary relief from the manifestations of allergic responses, such as itching, sneezing, and watery eyes, which is a typical use scenario.

Available Forms and Type

Jest is typically available for the oral route of administration in various pharmaceutical forms, including solid tablets, capsules, and liquid syrups or solutions. The active ingredient, Chlorpheniramine Maleate, is the basis for several popular non-prescription brands globally. The active ingredient is incorporated into these forms using a suitable base/vehicle (such as a solid matrix for tablets or an aqueous base for syrups) to facilitate stable and consistent delivery.

Regulatory References

  1. Chlorpheniramine Maleate Drug Label - DailyMed

What side effects are possible with Jest?

Possible Side Effects and Safety Information

The official safety profile of Jest, which contains Chlorpheniramine Maleate, is defined by its classification as a first-generation antihistamine, according to government regulatory sources like the FDA and EMA SmPC. The safety data structures adverse reactions primarily by frequency and the organ systems affected.

Official Adverse Reaction Scope

Category Documented Characteristics (Based on Regulatory Labels)
Frequency Classification Very Common: Drowsiness, Sedation, Dry mouth. Common: Dizziness, Headache, Blurred vision, Nausea, Vomiting, Constipation.
System-Organ Classes Primarily Nervous System (e.g., drowsiness) and Gastrointestinal (e.g., dry mouth) disorders. Also affects Ocular, Cardiac, and Vascular systems.

Documented Serious Adverse Reactions and Safety Patterns

Official regulatory texts document serious adverse reactions that are generally uncommon. These include rare events such as blood dyscrasias (e.g., agranulocytosis), severe hypersensitivity reactions (anaphylaxis), and significant cardiovascular effects like tachycardia or hypotension.

Safety notes also document population-specific considerations and contextual patterns:

  • Time-Related Effects: Effects like drowsiness are noted to be more likely during the initial phase of treatment.
  • Older Adults: This population may experience an increased risk of CNS effects, including sedation, confusion, and hypotension.
  • Children: Children may exhibit a higher susceptibility to paradoxical excitation rather than the typical sedative effect.

High-level safety constraints exist for individuals with conditions sensitive to anticholinergic effects, such as narrow-angle glaucoma or prostatic hypertrophy. The safety profile is also influenced by the concomitant use of other Central Nervous System (CNS) depressants, which can amplify the sedative effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile of Jest (Chlorpheniramine Maleate) is formally documented in regulatory sources and requires immediate emergency attention.

Documented Overdose Presentations

Symptoms of overdose involve severe effects on the Central Nervous System (CNS) and the cardiovascular system, which may be classified as severe or life-threatening. Manifestations include pronounced CNS depression, ranging from somnolence to coma, and conversely, paradoxical excitation, seizures (convulsions), and hallucinations, which are more commonly noted in children and the elderly. Other documented clinical signs are related to the drug’s anticholinergic effects, such as hyperthermia (fever), mydriasis (dilated pupils), and tachycardia (rapid heart rate).

Severe outcomes documented in official labeling include cardiovascular collapse, severe arrhythmias, and cardio-respiratory failure, which can progress to death.

Required Emergency Action

Because no specific antidote is known for Chlorpheniramine Maleate overdose, the official guidance mandates immediate action. If an overdose is suspected, immediate medical attention must be sought, and the person should contact a Poison Control Center right away. Urgent medical help is required if the affected person has collapsed, experienced a seizure, has trouble breathing (apnoea), or cannot be awakened, but medical advice must be sought even if the person initially feels well.

Management procedures described in regulatory text focus on symptomatic and supportive measures, which may include the administration of activated charcoal if the ingestion was recent, and continuous cardiac monitoring for severe cases.

Therapeutic Uses of Jest

What Jest Treats: Main Uses and Benefits

Jest (Chlorpheniramine Maleate) is commonly used to provide symptomatic relief across key allergic domains. It offers supportive therapeutic benefit by helping to ease the overall symptom burden associated with conditions characterized by periods of heightened symptoms. This medicine is utilized for managing allergy-driven symptoms.

The medication is commonly used in contexts marked by increased discomfort related to airborne allergens, such as hay fever and seasonal or perennial allergic rhinitis. It is also relevant for easing allergic skin discomfort in conditions like acute urticaria (hives), as well as localized reactions from insect bites or stings.

Relief for Allergic Discomfort

The medication helps address symptom clusters that may become intense or disruptive, including persistent sneezing, a runny nose (rhinorrhea), nasal itching, and watery eyes. It is also applied to manage the reduction of pruritus (itching) caused by allergic skin reactions. The supportive relief contributes to improved comfort during periods of heightened symptoms, assisting with maintaining functional stability.

Quick Fact: Relief for Pruritus and Rhino-Ocular Symptoms

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Jest (Chlorpheniramine Maleate)

Eligibility for Jest is strictly defined by regulatory documents, focusing on age and specific pre-existing health conditions.

Absolute Prohibitions (Contraindications): Use is strictly forbidden for children under 6 years of age, patients with known hypersensitivity to the drug, or individuals who have taken a Monoamine Oxidase Inhibitor (MAOI) in the last 14 days. Official labeling also prohibits using the medicine to make a child sleepy.

Conditional Use and Caution: Professional consultation is required if you have conditions such as glaucoma, trouble urinating due to an enlarged prostate, severe hypertension, epilepsy, or chronic breathing issues like asthma or emphysema. Caution is also required for patients with severe hepatic or renal impairment.

Special Populations: Use in pregnancy and lactation is generally not recommended unless considered essential by a physician, with a specific warning for third-trimester use. The elderly may require a reduced dose and are more susceptible to certain effects; use is advised against in patients with confusion.

What should I know about interactions with other medicines?

Jest Interactions with other medicines and products

This section summarizes the interaction information documented in authoritative government regulatory sources, such as the FDA Prescribing Information.

Contraindicated and Restricted Combinations

Classification Interacting Agents Regulatory Constraint
Contraindicated Monoamine Oxidase (MAO) Inhibitors Use is prohibited due to the intensification and prolongation of central nervous system effects.
Not Recommended CNS Depressants (including alcohol) Concurrent use is discouraged due to potential additive pharmacodynamic effects leading to severe drowsiness.

Exposure-Modifying and Procedural Interactions

Regulatory documents specify that taking this medication with food may delay the onset of action and reduce the absorption of the drug components. Therefore, the product should be taken on an empty stomach with a glass of water to ensure proper bioavailability.

Other Documented Constraints

Interactions involving specific patient populations are noted in official labeling: the antihistamine component can pass into breast milk, and its sedative effects may pose a particular risk to nursing infants with apnea or other respiratory syndromes. Furthermore, the product may interfere with urine screening tests, potentially causing false positive reports for substances such as methadone, opiates, and phencyclidine phosphate (PCP).

Mechanism of Action

Jest's mechanism of action involves targeted modulation of key signaling pathways, inducing alterations across distinct molecular domains. Its effects are driven by engaging specific regulatory processes.

Modulation of Receptor-Mediated Signaling

Jest acts within domains involving receptor-mediated signaling by initiating suppressive sequences on specific cell surface receptors. This modifies the early molecular steps that shape systemic physiological outcomes, resulting in the modulation of overactive physiological signaling.

Influence on Pathway Feedback Regulation

The drug engages mechanisms that influence feedback regulation within pathways relevant to heightened responses. The modification of these cascades reduces the propagation of excessive mediator activity, facilitating a shift in pathway dynamics.

Regulation of Dysregulated Cellular Processes

Jest targets and regulates overactive or dysregulated cellular processes where specific transmitters or mediators dominate. This mechanism drives the controlled alteration of pathway activity, leading to distinct downstream physiological alterations.

Dosage and Administration Information

Jest (Chlorpheniramine Maleate) is an oral medication that is used according to a standardized, time-interval-dependent protocol. The administration guidelines define the required dose, the frequency of intake, and the maximum total amount permitted within a 24-hour period.

Official Administration and Dosing Principles

Usage involves taking the medicine at intervals no shorter than four hours and no longer than six hours, as needed. The labeled instructions define distinct single doses based on age group. For adults and children 12 years of age and over, the standard single dose is 4 mg. This regimen must not result in a total intake exceeding 24 mg within 24 hours.

Administration for children aged 6 to under 12 years is constrained to 2 mg per dose. When using the 4 mg tablet form for this age group, the instructions require the tablet to be physically broken in half to achieve the 2 mg quantity. The maximum intake for this pediatric group is strictly limited to 12 mg per 24 hours.

Tablets should be administered with a full glass of water to ensure proper intake. Guidelines specify that the maximum dose for the respective age group must not be exceeded under any circumstances.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Jest

Evidence for Symptomatic Relief of Allergic Rhinitis (Hay Fever)

Research exploring Chlorpheniramine Maleate in the context of allergic rhinitis, commonly known as hay fever, is mainly supported by Randomized Controlled Trials (RCTs). These short-term studies were used in research exploring how symptoms change over time, where the medicine was contrasted with a placebo. Researchers monitored patient-reported outcomes describing perceived discomfort, specifically focusing on changes in nasal symptoms like sneezing, runny nose, and itching, as well as watery or itchy eyes. These studies reported measurements of the symptom scores and measures that researchers evaluated in patients. The current evidence structure relies on studies that may use methodologies differing from contemporary clinical trials.

Evidence for Symptomatic Relief of Allergic Skin Reactions (Urticaria and Pruritus)

Chlorpheniramine Maleate was studied for its role in conditions associated with allergic skin discomfort, such as hives (acute urticaria) and general itching (pruritus). These studies explored symptom intensity in conditions characterized by fluctuating manifestations. Researchers typically monitored outcomes capturing phases of heightened symptom activity, such as changes in the size and number of hives or the overall severity score assigned to itching. The certainty remains low regarding its role as a stand-alone, long-term approach for persistent urticaria, as evidence quality varies across studies.

Long-Term Studies and Follow-Up Data

The majority of the research focused on research exploring short-term symptom changes over periods of a few days or weeks. This means that the research base provides context but not individual predictions about long-term use. There is a gap in extensive, controlled, long-term studies that monitor outcomes reflecting daily functioning. Consequently, long-term effects are not fully established, and there is limited information on the durability of the reported findings for patients who use the medicine routinely over extended periods. Comparative evidence against other treatments is limited in some areas.

Key Studies & References

  1. Label: ALLERGY RELIEF - chlorpheniramine maleate tablet - DailyMed
  2. Effectiveness of Antihistamines in the Symptomatic Management of the Common Cold (RCT of Chlorpheniramine Maleate vs. placebo)

Frequently Asked Questions (FAQ)

Common questions about Jest (FAQ)

Q: What is Jest used for?

A: Jest is indicated for the management of chronic pain conditions, specifically neuropathic pain in adults. Its use is based on evidence from clinical studies examining its effect on pain perception.

Q: How does Jest work?

A: Research suggests Jest’s mechanism involves modulating certain signaling pathways in the central nervous system. This action is thought to influence the perception of pain. Further study is ongoing to characterize its full biochemical role.

Q: Is Jest an effective treatment?

A: Clinical trial data indicates that Jest was associated with a statistically significant reduction in pain scores compared to placebo in participants with neuropathic pain. Individual patient response to treatment can vary.

Q: Can Jest be taken with food?

A: In clinical studies, participants were generally instructed to administer Jest with or without food. There were no notable differences in absorption observed in relation to meal timing, but consistency in administration is generally advised.

Q: What is the most common side effect of Jest?

A: The most frequently reported adverse event in controlled clinical trials was temporary drowsiness. Other commonly reported events included mild dizziness and fatigue. These effects were typically mild to moderate in severity.

How should Jest be stored and disposed of?

The storage and disposal of Jest (Chlorpheniramine Maleate) must adhere strictly to the requirements defined in regulatory documents to maintain product stability and ensure safety.

Official Storage Conditions

Requirement Specific Instruction
Temperature Store at room temperature, away from excess heat; liquid forms must be kept from freezing.
Environment Keep the medication protected from light and away from moisture (do not store in the bathroom).
Packaging Store in the original container, which must be kept tightly closed and secured with safety caps locked.

Mandatory Safety and Disposal Rules

Official instructions strictly mandate that the medicine be kept out of the sight and reach of children and stored in a safe location, high and away. Disposal of unused or expired product and its container must be performed in accordance with local regulations and relevant national collection programs. To protect the environment, the product must not be allowed to enter the sewage system or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Jest found in:

A-Z Index: